Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

MOLN Molecular Partners AG

4,45

-0,05 (-1,11%)

Última atualização: 12:46:15

Atrasado em 15 minutos

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Molecular Partners (NASDAQ:MOLN)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

Click aqui para mais gráficos Molecular Partners.

Molecular Partners (NASDAQ:MOLN)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025

Click aqui para mais gráficos Molecular Partners.

Notícias Molecular Partners AG

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quinta, 6 de Março de 2025 (6 dias atrás) • Edgar (US Regulatory)

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Quinta, 6 de Março de 2025 (6 dias atrás) • Edgar (US Regulatory)

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
Quinta, 6 de Março de 2025 (6 dias atrás) • GlobeNewswire Inc.

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
Sexta, 28 de Fevereiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 13 de Janeiro de 2025 (2 meses atrás) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 13 de Janeiro de 2025 (2 meses atrás) • Edgar (US Regulatory)

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
Domingo, 12 de Janeiro de 2025 (2 meses atrás) • GlobeNewswire Inc.

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
Terça, 17 de Dezembro de 2024 (3 meses atrás) • GlobeNewswire Inc.

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Domingo, 8 de Dezembro de 2024 (3 meses atrás) • GlobeNewswire Inc.

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Quinta, 7 de Novembro de 2024 (4 meses atrás) • GlobeNewswire Inc.

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
Terça, 5 de Novembro de 2024 (4 meses atrás) • GlobeNewswire Inc.

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Quinta, 31 de Outubro de 2024 (4 meses atrás) • GlobeNewswire Inc.

Mais Notícias de Molecular Partners AG

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições